Novel osteobiologics and biomaterials in the treatment of spinal disorders

Wellington K. Hsu, Christina L. Goldstein, Mohammed F. Shamji, Sam K. Cho, Paul M. Arnold, Michael G. Fehlings, Tom E. Mroz

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Spinal osteobiologics have evolved substantially in this century after the development of many product categories such as growth factors, allograft, and stem cells. The indications for the use of novel biologics within spine surgery are rapidly expanding as the mechanism of each is elucidated. While the knowledge base of bone morphogenetic protein increases with each subsequent year, the application of new nanotechnology and cell-based strategies are being reported. This review will discuss the most recent data in novel osteobiologics, and where we could use future study.

Original languageEnglish
Pages (from-to)S100-S107
JournalClinical Neurosurgery
Issue number3
StatePublished - 1 Mar 2017


  • Bonemorphogenetic protein
  • Nanotechnololgy
  • Osteobiologics
  • Spinal biologics
  • Spinal fusion
  • TNF-α inhibitors


Dive into the research topics of 'Novel osteobiologics and biomaterials in the treatment of spinal disorders'. Together they form a unique fingerprint.

Cite this